Sustained illness burden over time among Australians with myalgic encephalomyelitis/chronic fatigue syndrome.
Weigel, Breanna, Eaton-Fitch, Natalie, Thapaliya, Kiran et al. · PloS one · 2025 · DOI
Quick Summary
This Australian study followed 32 people with ME/CFS over one year to document how the illness affects their lives. Participants reported an average of 30 symptoms at each check-in, with no improvement over the year, and their quality of life was significantly worse than the general population. The findings show that ME/CFS causes sustained, long-term disability that requires better support and recognition from Australian healthcare and disability services.
Why It Matters
This study provides longitudinal evidence that ME/CFS causes persistent, non-improving disability over time, which is critical for advocating policy reform and disability recognition in Australia. The sustained impairment documented here challenges any assumptions that symptoms naturally improve and supports the case for increased healthcare resources and social support services for people with ME/CFS.
Observed Findings
Participants reported a median of 30 symptoms at each of three assessments over 12 months with no statistically significant changes.
Quality of life measures were significantly lower in people with ME/CFS compared to Australian population norms at all timepoints.
Overall health status, physical health, and ability to work were identified as the most substantially impacted domains.
The most common symptoms were also the most severe in their presentation.
Symptom burden and patient-reported outcomes remained stable across the entire 12-month study period.
Inferred Conclusions
ME/CFS causes sustained, persistent illness burdens that do not naturally improve over time, indicating a chronic rather than self-limiting condition.
The profound impairment in quality of life and daily functioning necessitates policy reform to formally recognize ME/CFS as a disability in Australia.
People with ME/CFS require improved access to disability support services and social support given the stability and severity of their illness burden.
Remaining Questions
What factors (if any) might lead to improvement or worsening of symptoms in people with ME/CFS, and why did this cohort show stability?
How do outcomes differ between people with ME/CFS in Australia versus other countries with different healthcare and disability support systems?
What This Study Does Not Prove
This study does not identify what causes ME/CFS symptoms or why they remain stable over time—it only documents that they do. The small sample size (n=32) and lack of a control group mean findings cannot be generalized to all people with ME/CFS or explain the underlying biological mechanisms. The study also cannot determine whether different treatment approaches might change outcomes.